Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Stakeholder Insight - Inflammatory Bowel Disease - Debate over early aggressive treatment continues (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 19/12/2007
- Report Title: Stakeholder Insight - Inflammatory Bowel Disease - Debate over early aggressive treatment continues
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 297
Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
Scope
Analysis of the inflammatory bowel disease market based on a survey of 180 gastroenterologists supported by key opinion leader interviews
Overview of epidemiology and patient segmentation in IBD
Influences on gastroenterologists' prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure
Highlights
Clinical guidelines recommend a step-up treatment approach. However, this survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and this approach will become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but this survey suggests currently only 30% of these patients go on to receive Humira.
Shire's Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.
Reasons to Purchase
Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
Scope
Analysis of the inflammatory bowel disease market based on a survey of 180 gastroenterologists supported by key opinion leader interviews
Overview of epidemiology and patient segmentation in IBD
Influences on gastroenterologists' prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure
Highlights
Clinical guidelines recommend a step-up treatment approach. However, this survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and this approach will become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but this survey suggests currently only 30% of these patients go on to receive Humira.
Shire's Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.
Reasons to Purchase
Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
